Hang Seng Index
Sino Biopharm
A large Chinese pharmaceutical company developing prescription drugs in hepatology, oncology, and cardiovascular care. Hang Seng Index constituent. Baseline node ahead of value-chain research; promoted to a full node once AI question demand is observed.
1177.HK Updated Jul 11, 2026 2 AI consumers
Annual return · 2026-07-10'21-25%'22-13.5%'23-36.8%'24+2.4%'25+138.7%YTD-20.9%
Money in ▸·
Sino Biopharmapprox. CN¥26.2B
▸ Money out·
Financials & Segments
- Total revenue · approx. CN¥26.2B (FY2023)
- Segments · Oncology · Liver disease · Cardio-cerebral & respiratory
Revenue from
No refined links yet.
Pays to
No refined links yet.